A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

March 1, 2024

Study Completion Date

March 1, 2024

Conditions

Solid TumorsNeoplasmsMalignant Tumor

Interventions

DRUG

ES102

ES102 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.

Trial Locations (1)

Jilin Cancer Hospital, Changchun

All Listed Sponsors

lead

Elpiscience Biopharma, Ltd.

INDUSTRY

NCT04730843 - A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter